Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Neuriterx** is a topical over-the-counter cream containing **0.05% or 0.075% capsaicin**, a naturally occurring compound derived from chili peppers, formulated for the symptomatic relief of neuropathic pain symptoms such as burning, tingling, numbness, swelling, and poor balance associated with peripheral neuropathy. It acts primarily by activating **transient receptor potential cation channel subfamily V member 1 (TRPV1)** on nociceptive nerve fibers, leading to initial depolarization followed by defunctionalization—a prolonged desensitization that reduces pain signaling through mechanisms including substance P depletion, mitochondrial disruption, and nerve terminal retraction. Developed as a patent-pending neuropathy management product by **Semprae Laboratories Inc.**, it provides rapid relief within minutes of application without systemic absorption risks typical of prescription analgesics.[3][4][6][9]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Neuriterx.